Source: https://patents.google.com/patent/US8226975?oq=5%2C987%2C610
Timestamp: 2018-06-22 04:37:00
Document Index: 387352105

Matched Legal Cases: ['Application No. 2005', 'Application No. 11159754', 'Application No. 2006270008', 'Application No. 200380106534', 'Application No. 200680034397', 'art 2', 'art 1', 'art 2', 'Application No. 2005', 'Application No. 2005', 'Application No. 2003304204', 'Application No. 2006322076', 'Application No. 2504317', 'Application No. 2504317', 'Application No. 03816990', 'Application No. 03816990', 'Application No. 2219', 'Application No. 168279', 'Application No. 168279', 'Application No. 168279', 'Application No. 188406', 'Application No. 188406', 'Application No. 10', 'Application No. 10', 'Application No. 540087', 'Application No. 540087', 'Application No. 564543', 'Application No. 565300', 'Application No. 565300', 'Application No. 565300', 'Application No. 592217', 'Application No. 200380106534', 'Application No. 200680034397', 'Application No. 03816990', 'Application No. 03816990', 'Application No. 06787716', 'Application No. 200380106534']

US8226975B2 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof - Google Patents
US8226975B2
US8226975B2 US11634343 US63434306A US8226975B2 US 8226975 B2 US8226975 B2 US 8226975B2 US 11634343 US11634343 US 11634343 US 63434306 A US63434306 A US 63434306A US 8226975 B2 US8226975 B2 US 8226975B2
US11634343
US20070196461A1 (en )
US11634343 2005-12-08 2006-12-05 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Active 2028-08-15 US8226975B2 (en)
US74846805 true 2005-12-08 2005-12-08
US11634343 US8226975B2 (en) 2005-12-08 2006-12-05 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13527213 US8632804B2 (en) 2005-12-08 2012-06-19 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13664181 US8679532B2 (en) 2005-12-08 2012-10-30 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13666420 US8642075B2 (en) 2005-12-08 2012-11-01 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13675587 US8673349B2 (en) 2005-12-08 2012-11-13 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13675559 US8673348B2 (en) 2005-12-08 2012-11-13 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US14080922 US20140072620A1 (en) 2005-12-08 2013-11-15 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US14987508 US9402845B2 (en) 2005-12-08 2016-01-04 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15066360 US20160184302A1 (en) 2005-12-08 2016-03-10 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15066346 US20160184301A1 (en) 2005-12-08 2016-03-10 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15205918 US9511082B2 (en) 2005-12-08 2016-07-08 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15205925 US9549939B2 (en) 2005-12-08 2016-07-08 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15241439 US9549925B2 (en) 2005-12-08 2016-08-19 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15376086 US20170087155A1 (en) 2005-12-08 2016-12-12 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13527213 Continuation US8632804B2 (en) 2005-12-08 2012-06-19 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20070196461A1 true US20070196461A1 (en) 2007-08-23
US8226975B2 true US8226975B2 (en) 2012-07-24
US11634343 Active 2028-08-15 US8226975B2 (en) 2005-12-08 2006-12-05 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13527213 Active US8632804B2 (en) 2005-12-08 2012-06-19 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13664181 Active US8679532B2 (en) 2005-12-08 2012-10-30 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13666420 Active US8642075B2 (en) 2005-12-08 2012-11-01 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13675587 Active US8673349B2 (en) 2005-12-08 2012-11-13 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US13675559 Active US8673348B2 (en) 2005-12-08 2012-11-13 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US14080922 Abandoned US20140072620A1 (en) 2005-12-08 2013-11-15 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US14987508 Active US9402845B2 (en) 2005-12-08 2016-01-04 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15066346 Abandoned US20160184301A1 (en) 2005-12-08 2016-03-10 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15066360 Abandoned US20160184302A1 (en) 2005-12-08 2016-03-10 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15205925 Active US9549939B2 (en) 2005-12-08 2016-07-08 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15205918 Active US9511082B2 (en) 2005-12-08 2016-07-08 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15241439 Active US9549925B2 (en) 2005-12-08 2016-08-19 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US15376086 Pending US20170087155A1 (en) 2005-12-08 2016-12-12 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US (14) US8226975B2 (en)
CA (3) CA2896083A1 (en)
WO (1) WO2007067520A3 (en)
US20130028960A1 (en) * 2005-12-08 2013-01-31 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9532986B2 (en) 2014-04-08 2017-01-03 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US6492560B2 (en) 1995-10-19 2002-12-10 The University Of Washington Discrete-length polyethylene glycols
US20050042341A1 (en) 2003-08-22 2005-02-24 Thomas Linda Valerie Natamycin dosage form, method for preparing same and use thereof
US20050113337A1 (en) 2001-05-29 2005-05-26 Tap Pharmaceutical Products, Inc. Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US20070081963A1 (en) 2005-10-12 2007-04-12 Regeron, Inc. Composition for improving skin conditions comprising human growth hormone as an active ingredient
US20080089927A1 (en) 2006-04-06 2008-04-17 Vladimir Malinin Methods for Coacervation Induced Liposomal Encapsulation and Formulations Thereof
US20090104256A1 (en) 2007-05-07 2009-04-23 Renu Gupta Methods of Treating Pulmonary Disorders with Liposomal Amikacin Formulations
US20090274754A1 (en) 2006-10-24 2009-11-05 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8100162B2 (en) 2005-07-22 2012-01-24 Airbus Deutschland Gmbh Guiding device for a device for producing fiber preforms by the TFP process for composite components
DE60012693T2 (en) 1999-02-08 2005-01-13 Alza Corp., Mountain View A process for the control of the liposome size
CA2424345A1 (en) 2000-10-16 2002-04-25 Aquilur Rahman Liposomal formulation of mitoxantrone
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
WO2011049960A9 (en) 2009-10-21 2011-08-18 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US9566234B2 (en) * 2012-05-21 2017-02-14 Insmed Incorporated Systems for treating pulmonary infections
WO2015061025A1 (en) 2013-10-22 2015-04-30 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
US5837279A (en) 1984-08-08 1998-11-17 The Lipsome Company, Inc. Encapsulation of ionizable agents in liposomes
US20100068257A1 (en) 2002-10-29 2010-03-18 Transave, Inc. Sustained Release of Antiinfectives
US20100260829A1 (en) 2002-10-29 2010-10-14 Transave, Inc. Sustained Release of Antiinfectives
Allen et al., "Effect of liposomes size and drug release properties of pharmacokinetics of encapsulated drug to rats," Pharmacology and Experimental Therapeutics, 226:539-544 (1983).
Andrews, J.M., "Determination of minimum inhibiory concentrations," Journal of Antimicrobial Chemotherapy, 48, Suppl S1, 5-16 (2001).
Antos et al. (1995) Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. Pharmacological Research 32(1/2): 84-87.
Bakker-Woudenberg et al. (1995) Efficacy of gentamicin or ceftazidine entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. Journal Infectious Diseases 171:938-947.
Ball, V. et al., "Complexation mechanism of bovine serum albumin and poly(allylamine hydrochloride)," J. Phys. Chem. B., 106(9):2357-2364 (2002).
Bangham, A. D., Introduction, "Liposomes: An Historical Perspective," in: Liposomes, Ostro, M. J. (ed.), pp. 1-29, Marcel Dekker, Inc., New York (1983).
Bargoni et al. (2001) Transmucosl transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-Tissue distribution. Pharmacological Research 43(5): 497-502.
Bargoni et al. (2001) Transmucosl transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II—Tissue distribution. Pharmacological Research 43(5): 497-502.
Beaulac et al. (1997) In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. Journal Microencapsulation 14(3): 335-348.
Beaulac et al. (1999) Aerolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. Journal Drug Targeting 7(1): 33-41.
Bermudez et al. (1999) Treatment of Disseminated Mycobacterium avium Complex Infection of Beige Mice with Liposome-Encapsulated Aminoglycosides. Journal Infect. Dis. 161: 1262-1268.
Bucke et al., "Surface-Modified Amikacin-Liposomes: Organ Distribution and Interaction With Plasma Proteins," Journal Drug Targeting 5(2): 99-108 (1997).
Cantin, A. M. et al., "Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection," Am. J. Respir. Crit. Care Med., 160:1130-1135 (1999).
Carlier, M. B. et al., "Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies," Antimicrobial Agents and Chemotherapy, 23(3):440-449 (1983).
Cash, H. A. et al., "A rat model of chronic respiratory infection with Pseudomonas aeruginosa," American Review of Respiratory Disease, 119(3):453-459 (1979).
Challoner, P. B. et al., "Gamma Scintigraphy Lung Deposition Comparison of TOBI in the PARI LC PLUS Nebulizer and the Aerodose Inhaler," American Thoracic Society 97th International Conference, San Francisco, California, Aerogen, Inc. (2001).
Chambless, J. D. et al., "A three-dimensional computer model of four hypothetical mechanisms protecting biofilms from antimicrobials," Appl. Environ. Microbiol., 72(3):2005-2013 (2006).
Chapman, D., "Physicochemical Properties of Phospholipids and Lipid-Water Systems," In: Liposome Technology, Chapter 1, vol. I, Preparation of Liposomes, Gregoriadis G. (ed.), CRC Press, Inc., Boca Raton, Florida, pp. 1-18 (1984).
Chmiel, J. F. et al., "State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?", Respiratory Research, 4:8-20 (2003).
Comis, R. L., "Carboplatin in the treatment of non-small cell lung cancer: a review," Oncology, 50(2):37-41 (1993).
Costerton, J. W. et al., "Bacterial biofilms: A common cause of persistent infections," Science, 284:1318-1322 (1999).
Couvreur, P. et al., "Liposomes and nanoparticles in the treatment of intracellular bacterial infections," Pharmaceutical Research, 8(9):1079-1085 (1991).
Cynamon et al. (1989) Liposome-Encapsulated-Amikacin Therapy of Mycobacterium avium Complex Infection in Geige Mice. Antimicrobial Agents and Chemotherapy 33(8): 1179-1183.
Damaso, D. et al., "Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics," The Journal of Infectious Diseases, 134:S394-S390 (1976).
Decision of Refusal for Japanese Patent Application No. 2005-500829, dated Feb. 14, 2012 .
Dees et al. (1990) The mechanism of enhanced intraphagocytic killing of bacteria by liposomes containing antibiotics. Veterinary Immunology and Immunopathology 24: 135-146.
Demaeyer et al. (1993) Disposition of liposomal gentamicin following intrabronchial administration in rabbits. Journal Microencapsulation 10(1): 77-88.
Deol et al., "Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubular drugs in mice," Biochemica et Biophysica Acta, 1334:161-172 (1997).
Dong, C. et al., "Acacia-gelatin microencapsulated liposomes: preparation, stability and release of acetylsalicylic acid," Pharmaceutical Research, 10(1):141-146 (1993).
Doring, G. et al., "Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus," Eur Respir J., 16(4):749-767 (2000).
Drenkard, E. et al., "Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation," Nature, 416:740-743 (2002).
Ehlers et al. (1996) Liposomal amikacin for treatment of M. avium Infections in clinically relevant experimental settings. Zbl. Bakt. 284: 218-231.
European Search Report for European Patent Application No. 11159754, mailed Jun. 22, 2011.
Examiner's First Report for Australian Application No. 2006270008, dated Dec. 10, 2010.
Fielding et al. (1999) Pharmacokinetics and Urinary Excretion of Amikacin in Low-Clearance Unilamellar Liposomes after a Single or Repeated Intravenous Administration in the Rhesus Monkey. Antimicrobial Agents and Chemotherapy 43(3): 503-509.
First Office Action for Chinese Patent Application No. 200380106534.2, dated Aug. 11, 2006.
First Office Action for Chinese Patent Application No. 200680034397.X, dated Jan. 22, 2010 .
First Office Action for Mexican Patent Application No. PA/a/2005/004580, mailed Jan. 30, 2008.
Fountain et al. (1985) Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. Journal Infectious Diseases 152(3): 529-535.
Geller, D. E. et al., "Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis," Chest, 122(1):219-226 (2002).
Gibson, R. L. et al., "Pathophysiology and management of pulmonary infections in cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, 168(8):918-951 (2003).
Gibson, R. L. et al., "Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, 167(6):841-849 (2003).
Gilbert, B. E. et al., "Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol," American Journal of Respiratory and Critical Care Medicine, 156(6):1789-1793 (1997).
Gleiser, C. A. et al., "Pathology of experimental respiratory anthrax in Macaca mulatta," Brit. J. Exp. Path., 44:416-426 (1963).
Gonzales-Rothi, R. J. et al., "Liposomes and pulmonary alveolar macrophages: functional and morphologic interactions," Experimental Lung Research, 17:685-705 (1991).
Goss, C. H. et al., "Update on cystic fibrosis epidemiology," Current Opinion in Pulmonary Medicine, 10(6):510-514 (2004).
Gunther, A. et al., "Surfactant alteration and replacement in acute respiratory distress syndrome," Respiratory Research, 2(6): 353-364 (2001).
Hagwood, S. et al., "Structure and properties of surfactant protein B," Biochimica et Biophysica Acta., 1408:150-160 (1998).
Hansen, C. R. et al., "Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: an observational cohort study," Journal of Cystic Fibrosis, 4(1):35-40 (2005).
Hoffman, L. R. et al., "Aminoglycoside antibiotics induce bacterial biofilm formation," Nature, 436:1171-1175 (2005).
Howell, S. B., "Clinical applications of a novel sustained-release injectable drug delivery system: Depofoam Technology," Cancer Journal, 7:219-227 (2001).
Hrkach, J. S. et al., "Poly(L-Lactic acid-co-amino acid) graft copolymers: A class of functional biodegradable biomaterials," In: Hydrogels and Biodegradable Polymers for Bioapplications, Chapter 8, ACS Symposium Series No. 627, Ottenbrite, R. M. et al. (eds.), American Chemical Society, pp. 93-102 (1996).
Hrkach, J. S. et al., "Synthesis of poly(L-lactic acid-co-L-lysine) graft copolymers," Macromolecules, 28:4736-4739 (1995).
Hung, O. R. et al., "Pharmacokinetics of inhaled liposome-encapsulated fentanyl," Anesthesiology, 83(2): 277-284 (1995).
Hunt, B. E. et al., "Macromolecular mechanisms of sputum inhibition of tobramycin activity," Antimicrobial Agents and Chemotherapy, 39(1):34-39 (1995).
Ikegami, M. et al., "Surfactant protein metabolism in vivo," Biochimica et Biophysica Acta, 1408:218-225 (1998).
International Preliminary Report on Patentability for International Application No. PCT/US2006/027859, dated Jan. 22, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2006/046360, dated Jun. 11, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2007/008404, dated Oct. 21, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2007/008500, dated Oct. 21, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2008/062469, dated Nov. 10, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2008/062868, dated Nov. 10, 2009.
International Preliminary Report on Patentability for International Application No. PCT/US2009/060468, dated Apr. 19, 2011.
International Search Report and Written Opinion for International Application No. PCT/US2006/027859, mailed Aug. 14, 2007.
International Search Report and Written Opinion for International Application No. PCT/US2006/046360, mailed Oct. 17, 2007.
International Search Report and Written Opinion for International Application No. PCT/US2007/008404, mailed Sep. 26, 2008.
International Search Report and Written Opinion for International Application No. PCT/US2007/008500, mailed Sep. 26, 2008.
International Search Report and Written Opinion for International Application No. PCT/US2008/062469, mailed Sep. 18, 2008.
International Search Report and Written Opinion for International Application No. PCT/US2008/062868, mailed Sep. 18, 2008.
International Search Report for International Application No. PCT/US2003/034240, mailed Jul. 12, 2005.
Janoff, A. S. et al., "Unusual lipid structures selectively reduce the toxicity of amphotericin B," Proc. Nat. Acad. Sci. USA, 85:6122-6126 (1988).
Johansson, J., "Structure and properties of surfactant protein C," Biochimica et Biophysica Acta, 1408:161-172 (1998).
Katare, O. P. et al., "Enhanced in vivo Performance of Liposomallndomethacin Derived From Effervescent Granule Based Proliposomes," J. Microencapsulation, 12(5):487-493 (1995).
Kesavalu et al. (1990) Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle 71: 215-218.
Kim and Kim (1990) Pharmacokinetics of intravitreally injected liposomes encapsulated tobramycin in normal rabbits. Yonsei Medical Journal 31(4): 308-314.
Klemens et al. (1990) Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrobial Agents and Chemotherapy 34(6) 967-970.
Knoch et al. (Expert Opin. Drug Deliv. 2005; 2(2): 377-390). *
Lagace et al. (1991) Liposome-encapsulated antibiotics: preparation , drug release and antimicrobial activity against Pseudomona aeruginosa. Journal Microencapsulation 8(1): 53-61.
Landyshev, Y. S. et al., "Clinical and experimental aspects of liposomal hydrocortisone treatment of bronchial asthma," Ter. Arkh., 74(8):45-48 (2002).
Lass, J. S. et al., "New advances in aerosolised drug delivery: vibrating membrane nebuliser technology," Expert Opin Drug Deliv., 3(5):693-702 (2006).
Le Brun, P. P. H. et al., "A review of the technical aspects of drug nebulization," Pharmacy World & Science, 22(3):75-81 (2000).
Le Brun, P. P. H. et al., "Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients," European Journal of Pharmaceutics and Biopharmaceutics, 54:25-32 (2002).
Le Brun, P. P. H. et al., "Inhalation of tobramycin in cystic fibrosis part 1: The choice of a nebulizer," International Journal of Pharmaceutics, 189:205-214 (1999).
Le Brun, P. P. H. et al., "Inhalation of tobramycin in cystic fibrosis part 2: Optimization of the tobramycin solution for a jet and ultrasonic nebulizer," International Journal of Pharmaceutics, 189:215-225 (1999).
Lutwyche et al. (1998) Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrobial Agents and Chemotherapy 42(10) 2511-2520.
Marier et al. (2003) Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. Journal Antimicrobial Chemotherapy 52: 247-252.
Marier et al. (Antimicrobial Agents and Chemotherapy. Dec. 2002; 46(2): 3776-3781). *
Martini, W. Z. et al. , "Lung surfactant kinetics in conscious pigs," Am J Physiol., 277(1 Pt 1): E187-E195 (1999).
Mendelman, P. M. et al., "Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum," American Review of Respiratory Disease, 132(4):761-765 (1985).
Mohanty, B. et al., "Systematic of alcohol-induced simple coacervation in aqueous gelatin solutions," Biomacromolecules, 4:1080-1086 (2003).
Morgan et al. (1980) Preparation and properties of liposome-associated gentamicin. Antimicrobial Agents and Chemotherapy 17(4) 544-548.
Myers, M. A. et al., "Pulmonary effects of chronic exposure to liposome aerosols in mice," Experimental Lung Research, 19:1-19 (1993).
Newton, D. W. et al., Chapter 4: "Coacervation: Principles and Applications," In: Polymers for Controlled Drug Delivery, Tarcha, P. J. (ed.), CRC Press, Boca Raton, pp. 67-81 (1991).
Nightingale et al. (1993) Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrobial Agents and Chemotherapy 37(9) 1869-1872.
Niven, R. W. et al., "Nebulization of liposomes. II. The effects of size and modeling of solute release profiles," Pharmaceutical Research, 8(2):217-221 (1991).
Niven, R. W. et al., "Nebulization of liposomes. III. The effects of operating conditions and local environment," Pharmaceutical Research, 9(4):515-520 (1992).
Notification of Reasons for Refusal for Japanese Patent Application No. 2005-500829, dated Feb. 15, 2011 .
Notification of Reasons for Refusal for Japanese Patent Application No. 2005-500829, dated Jul. 6, 2010 .
Office Action for Australian Patent Application No. 2003304204, mailed Jun. 25, 2008.
Office Action for Australian Patent Application No. 2006322076, mailed Sep. 23, 2011.
Office Action for Canadian Patent Application No. 2504317, dated Jan. 27, 2011.
Office Action for Canadian Patent Application No. 2504317, dated Jun. 16, 2010.
Office Action for Egyptian Patent Application No. PCT 84/2008.
Office Action for European Application No. 03816990.0, mailed Apr. 24, 2009.
Office Action for European Application No. 03816990.0, mailed Jun. 17, 2011.
Office Action for Indian Patent Application No. 2219/delnp/2005, dated Jan. 3, 2007.
Office Action for Israel Patent Application No. 168279, dated Aug. 17, 2009 .
Office Action for Israel Patent Application No. 168279, dated Jun. 23, 2008 .
Office Action for Israel Patent Application No. 168279, dated Nov. 3, 2010 .
Office Action for Israel Patent Application No. 188406, dated Apr. 26, 2010 .
Office Action for Israel Patent Application No. 188406, dated Jun. 13, 2011 .
Office Action for Korean Patent Application No. 10-2005-7007679, dated Dec. 26, 2011 .
Office Action for Korean Patent Application No. 10-2005-7007679, dated Jan. 18, 2011.
Office Action for Mexican Patent Application No. MX/a/2008/000425, dated Jun. 2, 2010.
Office Action for Mexican Patent Application No. MX/a/2008/012684, dated Apr. 5, 2011.
Office Action for Mexican Patent Application No. MX/a/2008/012684, dated Jul. 8, 2011.
Office Action for Mexican Patent Application No. MX/a/2010/000195, mailed Feb. 1, 2012.
Office Action for Mexican Patent Application No. MX/a/2010/000195, mailed Jul. 27, 2011.
Office Action for Mexican Patent Application No. PA/a/2005/004580, mailed Aug. 25, 2009.
Office Action for New Zealand Patent Application No. 540087, dated Jan. 4, 2008.
Office Action for New Zealand Patent Application No. 540087, dated Sep. 14, 2006.
Office Action for New Zealand Patent Application No. 564543, mailed Jan. 4, 2008.
Office Action for New Zealand Patent Application No. 565300, dated Feb. 24, 2011.
Office Action for New Zealand Patent Application No. 565300, dated May 31, 2011.
Office Action for New Zealand Patent Application No. 565300, dated Nov. 11, 2009.
Office Action for New Zealand Patent Application No. 592217, mailed Sep. 1, 2011.
Office Action for U.S. Appl. No. 10/696,389, mailed Apr. 2, 2007.
Office Action for U.S. Appl. No. 10/696,389, mailed Mar. 28, 2008.
Office Action for U.S. Appl. No. 10/696,389, mailed Nov. 14, 2008.
Office Action for U.S. Appl. No. 10/696,389, mailed Oct. 10, 2007.
Office Action for U.S. Appl. No. 11/185,448, mailed Dec. 17, 2009.
Office Action for U.S. Appl. No. 11/185,448, mailed Jun. 30, 2009.
Office Action for U.S. Appl. No. 11/398,859, mailed Jun. 4, 2010.
Office Action for U.S. Appl. No. 11/398,859, mailed Sep. 11, 2009.
Office Action for U.S. Appl. No. 11/696,343, mailed May 10, 2011.
Office Action for U.S. Appl. No. 11/696,343, mailed Oct. 21, 2011.
Office Action for U.S. Appl. No. 12/250,412, mailed Dec. 2, 2011.
Office Action for U.S. Appl. No. 12/250,412, mailed Jun. 27, 2011.
Office Action for U.S. Appl. No. 12/424,177, mailed Aug. 31, 2011.
Office Action for U.S. Appl. No. 12/424,177, mailed Mar. 16, 2012.
Office Action for U.S. Appl. No. 12/598,830, mailed Mar. 7, 2012.
Office Action for U.S. Appl. No. 12/748,756, mailed Jan. 27, 2012.
Omri et al. (1994) Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 38(5) 1090-1095.
Omri et al. (1995) Incorporation, release and in vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. Journal Antimicrobial Chemotherapy 36: 631-639.
Omri et al. (1996) Comparison of the Bactericidal Action of Amikacin, Netilmicin and Tobramtcin in Free and Liposomal Formulation against Pseudomonas aeruginosa. Chemotherapy 42: 170-176.
Pai, V. B. et al., "Efficacy and safety of aerosolized tobramycin in cystic fibrosis," Pediatric Pulmonology, 32(4):314-327 (2001).
Parsek, M. R. et al., "Acyl-homoserine lactone quorum sensing gram-negative bacteria: a signaling mechanism involved in associations with higher organisms," Proc. Nat. Acad. Sci., 97(16):6789-6793 (2000).
Patton, J. S. et al., "The lungs as a portal of entry for systemic drug delivery," Proc. Am. Thor. Soc., 1:338-344 (2004).
Petersen et al. (1996) Liposomal amikacin: improved treatment of Mycibacterium avium complex infection in the beige mouse model. Journal Antimicrobial Chemotherapy 38: 819-828.
Petkowicz, J. et al., "Hypoglycemic Effect of Liposome-Entrapped Insulin Administered by Various Routes into Normal Rats," Pol. J. Pharmacal. Pharrn., 41:299-304 (1989).
Pilewski, J. M. et al., "Role of CFTR in airway disease," Physiological Reviews, 79(1):5215-5255 (1999).
Poyner et al. (Journal of Controlled Release, 1995; 35: 41-48). *
Price et al. (1989) Enhanced effectiveness of intraperitoneal antibiotics administered via liposomal carrier. Arch Surgery 124: 1411-1415.
Price et al. (1992) Liposome delivery of aminoglycosides in burn wounds. Surgery, Gynecology &Obstetrics 174: 414-418.
Price et al. (1994) Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery, 115(4): 480-4487.
Price, K. E. et al., "Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates," The Journal of Infectious Diseases, 134:S249-S261 (1976).
Ramsammy et al. (1988) The effect of gentamicin on the biophysical properties of phosphatidic acid liposomes is influenced by the O-C=O group of the lipid. Biochemistry 27: 8249-8254.
Ramsammy et al. (1988) The effect of gentamicin on the biophysical properties of phosphatidic acid liposomes is influenced by the O—C=O group of the lipid. Biochemistry 27: 8249-8254.
Ramsey, B. W. et al., "Efficacy of aerosolized tobramycin in patients with cystic fibrosis," The New England Journal of Medicine, 328:1740-1746 (1993).
Ramsey, B. W. et al., "Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group," The New England Journal of Medicine, 340(1):23-30 (1999).
Roehrborn et al. (1995) Lipid-based slow-release formulation of amikacin sulfate reduces foreign body associated infections in mice. Antimicrobial Agents Chemotherapy 39: 1752-1755.
Sabra, W. et al., "Physiological responses of Pseudomonas aeruginosa PAO1 to oxidative stress in controlled microaerobic and aerobic cultures," Microbiology, 148:3195-3202 (2002).
Schiffelers et al. (2001) In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. Journal Pharmacology Experimental Therapeutics 298(1): 369-375.
Schiffelers et al. (2001) Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. International Journal Pharmaceutics 214: 103-105.
Schreier, H. et al., "Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep," International Journal of Pharmaceutics, 87(1-3):183-193 (1992).
Second Office Action for Chinese Patent Application No. 200380106534.2 [no date].
Second Office Action for Chinese Patent Application No. 200680034397.X, dated Feb. 9, 2011 .
Second Office Action for Mexican Patent Application No. PA/a/2005/004580, mailed May 9, 2008.
Shah, S. P. et al., "Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance," AAPS PharmSciTech, 5(4):e65:1-7 (2004).
Singh, P. K. et al., "Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms," Nature, 407:762-764 (2000).
Skubitz, K. M. et al., "Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial," Anti-Cancer Drugs, 11(7): 555-563 (2000).
Stott, P. W. et al., "Characterization of complex coacervates of some tricyclic antidepressants and evaluation of their potential for enhancing transdermal flux," Journal of Controlled Release, 41(3):215-227 (1996).
Summons to Attend Oral Hearing for European Application No. 03816990.0, mailed Dec. 21, 2011.
Supplementary European Search Report for European Application No. 03816990.0, mailed Jan. 12, 2009.
Supplementary European Search Report for European Application No. 06787716.7, mailed Dec. 29, 2011.
Swenson et al. (1990) Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrobial Agents and Chemotherapy 34(2) 235-240.
Swenson, C. E. et al., "Liposomal aminoglycosides and TLC G-65," Aids Patient Care, pp. 290-296 (1991).
Szoka, F. Jr. et al., "Comparative properties and methods of preparation of lipid vesicles (liposomes)," Ann. Rev. Biophys. Bioeng., 9:467-508 (1980).
Taylor, K. M. G. et al., "The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man," Pharmaceutical Research, 6(7):633-636 (1989).
Ten, R. M. et al., "Interleukin-2 liposomes for primary immune deficiency using the aerosol route," International Immunopharmacology, 2(2-3):333-344 (2002).
Third Office Action for Chinese Patent Application No. 200380106534.2, dated May 22, 2009 .
Third Office Action for Mexican Patent Application No. PA/a/2005/004580, mailed Dec. 10, 2008.
Thomas, D. A. et al., "Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers," Chest, 99(5):1268-1270 (1991).
Thomasin, C. et al., "Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 2. Parameters determining microsphere formation," Journal of Pharmaceutical Sciences, 87(3):269-275 (1998).
Trafny et al. (1995) Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I. Antimicrobial Agents and Chemotherapy 39(12) 2645-2649.
Vecellio, L., "The mesh nebuliser: a recent technical innovation for aerosol delivery," Breathe, 2(3):253-260 (2006).
Veldhuizen, R. et al., "The role of lipids in pulmonary surfactant," Biochimica et Biophysica Acta, 1408:90-108 (1998).
Vidgren, M. et al., "A study of 99m technetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers," International Journal of Pharmaceutics, 115:209-216 (1995).
Vitas et al. (1996) Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrobial Agents and Chemotherapy 40(1) 146-151.
Westerman, E. M. et al., "Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study," Journal of Cystic Fibrosis, 3(1):23-28 (2004).
Whitehead et al., "Kinetics and Toxicity of Liposomal and Conventional Amikacin in a Patient with Multidrug-Resistant Tuberculosis," Eur J Clin Microbiol Infect Dis 17: 794-797 (1998).
Wichert, B. V. et al., "Amikacin liposomes: characterization, aerosolization, and in vitro activity against Mycobacterium avium- intracellulare in alveolar macrophages," International Journal of Pharmaceutics, 78(23):227-235 (1992).
Wolff, R. K. et al., "Toxicologic testing of inhaled pharmaceutical aerosols," Critical Reviews in Toxicology, 23(4):343-369 (1993).
Worlitzsch, D. et al., "Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients," J. Clin. Invest., 109:317-325 (2002).
Written Opinion for International Application No. PCT/US2009/060468, mailed Jun. 24, 2010.
Xiu, L. et al., "Drug Resistant Analysis of Pseudomonas aeruginosa in Patients with Mechanical Ventilation," Med. J. Chin. PLA, 27(6):544-545 (2002).
Zeng et al. (1993) Intravitreal Pharmacokinetics of Liposome-encapsulated Amikacin in a Rabbit Model. Opthamology 100: 1640-1644.
Zhang et al. (1999) A Novel Method to Prepare Liposomes Containing Amikacin. Journal Microencapsulation 16(4): 511-516.
US8642075B2 (en) * 2005-12-08 2014-02-04 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20140072620A1 (en) * 2005-12-08 2014-03-13 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8673348B2 (en) * 2005-12-08 2014-03-18 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8673349B2 (en) * 2005-12-08 2014-03-18 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8632804B2 (en) * 2005-12-08 2014-01-21 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20130071469A1 (en) * 2005-12-08 2013-03-21 Insmed Incorporated Lipid-Based Compositions of Antiinfectives for Treating Pulmonary Infections and Methods of Use Thereof
US9402845B2 (en) * 2005-12-08 2016-08-02 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
EP3067047A1 (en) 2016-09-14 application
WO2007067520A2 (en) 2007-06-14 application
JP2009518411A (en) 2009-05-07 application
EP1962805B1 (en) 2016-07-06 grant
EP1962805A2 (en) 2008-09-03 application
CA2631872C (en) 2014-04-01 grant
US20130071469A1 (en) 2013-03-21 application
US20160317563A1 (en) 2016-11-03 application
EP3067046A1 (en) 2016-09-14 application
US20160354371A1 (en) 2016-12-08 application
US20160317564A1 (en) 2016-11-03 application
US20130028960A1 (en) 2013-01-31 application
CA2838111C (en) 2016-01-19 grant
US20130052260A1 (en) 2013-02-28 application
US20140072620A1 (en) 2014-03-13 application
US9549925B2 (en) 2017-01-24 grant
EP1962805A4 (en) 2013-01-02 application
CA2838111A1 (en) 2007-06-14 application
US9402845B2 (en) 2016-08-02 grant
JP5324223B2 (en) 2013-10-23 grant
DK1962805T3 (en) 2016-09-26 grant
US8673349B2 (en) 2014-03-18 grant
US8632804B2 (en) 2014-01-21 grant
US20160113927A1 (en) 2016-04-28 application
WO2007067520A3 (en) 2007-12-06 application
ES2594368T3 (en) 2016-12-19 grant
US8673348B2 (en) 2014-03-18 grant
US20160184302A1 (en) 2016-06-30 application
US20130071468A1 (en) 2013-03-21 application
US9511082B2 (en) 2016-12-06 grant
US8679532B2 (en) 2014-03-25 grant
US20070196461A1 (en) 2007-08-23 application
US20170087155A1 (en) 2017-03-30 application
CA2896083A1 (en) 2007-06-14 application
US20160184301A1 (en) 2016-06-30 application
US9549939B2 (en) 2017-01-24 grant
US8642075B2 (en) 2014-02-04 grant
US20130064883A1 (en) 2013-03-14 application
CA2631872A1 (en) 2007-06-14 application
US7879351B2 (en) 2011-02-01 High delivery rates for lipid based drug formulations, and methods of treatment thereof
Adi et al. 2010 Co-spray-dried mannitol–ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease
US20070065522A1 (en) 2007-03-22 Administration of high potency platinum compound formulations by inhalation